Revealing the potential of necroptosis-related genes in prognosis, immune characteristics, and treatment strategies for head and neck squamous cell carcinoma.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
21 Nov 2023
21 Nov 2023
Historique:
received:
10
07
2023
accepted:
09
11
2023
medline:
27
11
2023
pubmed:
22
11
2023
entrez:
21
11
2023
Statut:
epublish
Résumé
Necroptosis is a recently discovered apoptotic mechanism that has been linked to tumor formation, prognosis, and treatment response. However, the relationship between the TME and NRGs remains unclear. In this study, we analyzed the expression patterns of NRGs in 769 HNSCC cases from two distinct data sets. Our findings revealed distinct genetic groups and a correlation between patient clinical features, prognosis, TME cell infiltration characteristics, and NRG alterations. We then developed an NRG model to predict OS and confirmed its accuracy in predicting OS in HNSCC patients. Moreover, we have devised a precise nomogram that enhances the clinical utility of the NRG model substantially. The low-risk group had a better OS, and they were associated with immune suppression, more mutated genes, and higher TIDE scores. The risk score also had a significant correlation with the CSC index and susceptibility to anti-tumor agents. Our study provides insights into how NRGs affect prognosis, clinically significant features, TME, and immunotherapy response in HNSCC. With a better knowledge of NRGs in HNSCC, we could assess the prognosis and develop immunotherapy regimens that are more successful at opening up new doors.
Identifiants
pubmed: 37989855
doi: 10.1038/s41598-023-47096-7
pii: 10.1038/s41598-023-47096-7
pmc: PMC10663615
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20382Informations de copyright
© 2023. The Author(s).
Références
Biochim Biophys Acta Rev Cancer. 2021 Dec;1876(2):188593
pubmed: 34280474
Crit Rev Oncol Hematol. 2022 Oct;178:103778
pubmed: 35932993
Nat Rev Dis Primers. 2020 Nov 26;6(1):92
pubmed: 33243986
Cancer Cell. 2021 Oct 11;39(10):1293-1296
pubmed: 34597591
Front Immunol. 2021 Dec 15;12:807600
pubmed: 34987523
Front Immunol. 2021 Aug 12;12:708186
pubmed: 34456917
J Cancer Surviv. 2023 Apr;17(2):449-459
pubmed: 35368225
Expert Rev Anticancer Ther. 2015;15(8):943-54
pubmed: 26098949
Mol Cancer. 2019 May 23;18(1):100
pubmed: 31122251
Bioinformatics. 2012 Mar 15;28(6):882-3
pubmed: 22257669
Oncoimmunology. 2021 Oct 12;10(1):1987636
pubmed: 34676149
Int J Cancer. 2015 Dec 15;137(12):2846-57
pubmed: 26095926
Front Immunol. 2022 Jun 16;13:915837
pubmed: 35784326
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Dis Markers. 2022 Jul 9;2022:3968303
pubmed: 35855852
Lancet. 2021 Dec 18;398(10318):2289-2299
pubmed: 34562395
Curr Mol Biol Rep. 2017 Dec;3(4):218-229
pubmed: 29430386
Cancer Treat Rev. 2022 Sep;109:102442
pubmed: 35932549
PLoS One. 2020 Jan 30;15(1):e0228015
pubmed: 31999765
Front Immunol. 2022 May 18;13:877815
pubmed: 35663937
Front Bioeng Biotechnol. 2022 Jan 11;9:814813
pubmed: 35111740
Nat Rev Cancer. 2021 Oct;21(10):669-680
pubmed: 34272515
Bioinformatics. 2010 Jun 15;26(12):1572-3
pubmed: 20427518
JCI Insight. 2020 Sep 17;5(18):
pubmed: 32780723
J Cell Mol Med. 2022 Sep;26(17):4698-4709
pubmed: 35871768
Apoptosis. 2020 Jun;25(5-6):441-455
pubmed: 32418059
Trends Cancer. 2022 Jan;8(1):21-27
pubmed: 34627742
Nature. 2020 Jan;577(7791):556-560
pubmed: 31942077
Cancer Manag Res. 2020 Oct 20;12:10397-10409
pubmed: 33116894
J Oncol. 2022 Apr 27;2022:7099930
pubmed: 35528236
Curr Treat Options Oncol. 2022 Mar;23(3):415-438
pubmed: 35262852
Immunity. 2021 Dec 14;54(12):2701-2711
pubmed: 34910940
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Front Immunol. 2022 May 20;13:894580
pubmed: 35669772
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Nat Rev Cancer. 2018 May;18(5):269-282
pubmed: 29497144
Int J Nanomedicine. 2021 Aug 27;16:5909-5921
pubmed: 34475756
Oncotarget. 2019 Jul 08;10(43):4503-4504
pubmed: 31327986
Nature. 2019 Nov;575(7784):683-687
pubmed: 31748744
Biomed J. 2021 Oct;44(5):548-559
pubmed: 34649833
Radiother Oncol. 2016 Feb;118(2):238-43
pubmed: 26589131
J Exp Clin Cancer Res. 2022 Mar 31;41(1):119
pubmed: 35361234
Front Genet. 2022 Feb 16;13:842218
pubmed: 35251139
J Clin Oncol. 2008 Mar 10;26(8):1364-70
pubmed: 18323559
Front Oncol. 2022 Jun 22;12:904614
pubmed: 35814424
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Nat Rev Immunol. 2021 Oct;21(10):653-667
pubmed: 33911231
Nat Rev Clin Oncol. 2018 Jul;15(7):459-466
pubmed: 29666440
Front Immunol. 2022 Jun 24;13:894718
pubmed: 35812403
Cell Death Dis. 2019 Feb 25;10(3):193
pubmed: 30804337
Signal Transduct Target Ther. 2022 Jun 20;7(1):196
pubmed: 35725836
Theranostics. 2018 Feb 2;8(5):1361-1375
pubmed: 29507626
PLoS One. 2016 Nov 11;11(11):e0166422
pubmed: 27835699
Int J Mol Sci. 2021 Jan 04;22(1):
pubmed: 33406603
Cell. 2018 Oct 4;175(2):598-599
pubmed: 30290144
Am J Transl Res. 2022 Nov 15;14(11):7653-7669
pubmed: 36505334
Nat Rev Clin Oncol. 2022 Jul;19(7):441-457
pubmed: 35365796
Nature. 2020 Mar;579(7799):421-426
pubmed: 32188939